Emergent BioSolutions faced a challenging fourth quarter with total revenues falling to $148.7 million, primarily driven by a 41% drop in Naloxone sales due to generic competition. Despite the quarterly loss, the company achieved full-year profitability with net income of $52.6 million and reduced its debt by $100 million as part of its multi-year turnaround strategy.

Emergent BioSolutions reported a 26% decrease in total revenues to $222.2 million for Q1 2025 compared to Q1 2024, but net income surged by 656% to $68.0 million. The company's gross margin expanded to 50%, and adjusted EBITDA increased by 16% to $77.6 million, demonstrating improved profitability despite lower sales.

Emergent BioSolutions reported Q4 2024 revenue of $194.7 million, down 30% year-over-year. The company recorded a net loss of $31.3 million, reflecting a 37% improvement from the prior year. Adjusted EPS was $0.05, a significant rebound from the previous year's loss. Product sales, particularly for NARCAN and Anthrax MCM, declined, while Smallpox MCM saw strong growth.

Emergent BioSolutions reported a strong Q3 2024 with a 9% increase in total revenues to $293.8 million and a 144% increase in net income to $114.8 million compared to the prior year. Adjusted EBITDA also saw a significant rise of 432% to $105.3 million. The company has raised its full-year 2024 guidance, reflecting improved financial performance and strategic progress.

Emergent BioSolutions reported Q2 2024 total revenues of $254.7 million, exceeding prior guidance. The company experienced a net loss of $283.1 million and an adjusted EBITDA of $(10.1) million. They are updating their FY 2024 guidance and expect to exceed $200 million in debt reduction by the end of the year.

Emergent BioSolutions reported strong Q1 2024 results with revenue above guidance, improved net income, and progress on debt and expense management. Total revenue increased by 83% to $300.4 million, driven by growth across key products like NARCAN and Anthrax MCM. The company is focused on transforming its operations and strengthening its financial position.

Emergent BioSolutions reported Q4 2023 total revenues of $276.6 million, a decrease of 16% compared to Q4 2022. The company experienced a net loss of $49.5 million and an adjusted EBITDA of $3.4 million for the quarter. They launched OTC NARCAN, received FDA approval for CYFENDUS, and were awarded contracts for CYFENDUS, Ebanga, and RSDL.

Emergent BioSolutions reported Q3 2023 total revenues of $271 million, surpassing previous guidance. However, a pre-tax loss of $266 million was recorded, alongside an adjusted EBITDA of $20 million. The company is delaying the release of full earnings information and the filing of its 10-Q due to an identified overstatement of state deferred tax liability.

Emergent BioSolutions reported Q2 2023 total revenues of $338 million, exceeding prior guidance, and an adjusted EBITDA of $56 million. The company updated its FY 2023 guidance and provided an initial Q3 2023 revenue forecast. Strategic steps were announced to reduce investment in its CDMO business.

Emergent BioSolutions reported Q1 2023 total revenues of $165 million, exceeding prior guidance. However, the company experienced a net loss of $183 million and an adjusted EBITDA of negative $101 million. The company updated its FY 2023 guidance and provided initial Q2 2023 guidance.

Emergent BioSolutions reported Q4 2022 financial results, with total revenues of $331 million and a net loss of $88 million. The company's performance reflects a period of transition, with a focus on public health preparedness and a strategy for sustainable long-term growth and profitability.

Emergent BioSolutions reported a decrease in total revenues by 27% compared to Q3 2021, with revenues of $240.0 million. The company experienced a net loss of $75.7 million, a significant increase from the $32.7 million loss in the same period last year. The decrease in revenue was primarily driven by lower product sales and CDMO services.

Emergent BioSolutions reported a decrease in total revenues by 39% compared to Q2 2021, driven by a decline in CDMO services. Net loss was $(56.4) million, compared to a net income of $4.6 million in Q2 2021. The company is focusing on combating critical public health threats with core medical countermeasure and commercial businesses and executing its growth strategy with M&A opportunities.

Emergent BioSolutions reported first quarter 2022 financial results, with total revenues of $307.5 million, a net loss of $3.7 million, and an adjusted EBITDA of $36 million. The company temporarily suspended CDMO guidance pending further clarity on COVID-19 vaccine requirements.

Emergent BioSolutions reported financial results for the fourth quarter and year ended December 31, 2021. The company's performance in 2021 is attributed to their strategic focus and capable team. The company is encouraged by the stability and durability of their diversified business lines and R&D portfolio.

Emergent BioSolutions reported a decrease in total revenue by 15% compared to Q3 2020, with a net loss of $32.7 million. The company secured contract renewals, advanced its pipeline, and implemented organizational enhancements. They are confident in their 2024 growth plan.

Emergent BioSolutions reported a 1% increase in total revenues compared to Q2 2020, driven by growth in CDMO services and NARCAN® Nasal Spray, offset by declines in Anthrax vaccines and ACAM2000. Net income decreased significantly due to increased operating expenses, including inventory write-offs.

Emergent BioSolutions reported a significant increase in total revenues for Q1 2021, driven primarily by contract development and manufacturing services. Net income and adjusted EBITDA also saw substantial growth compared to the same period last year. However, the company revised its full-year 2021 financial forecast downwards, mainly due to adjustments in CDMO services revenues.

Emergent BioSolutions reported a strong financial performance for Q4 2020, with a 62% increase in total revenues compared to Q4 2019, driven primarily by increased contract development and manufacturing (CDMO) services revenues. Net income and adjusted EBITDA also saw significant increases. The company reaffirmed its full year 2021 forecast.

Emergent BioSolutions reported a 24% increase in total revenues for Q3 2020, driven by growth in contract development and manufacturing services. Net income decreased slightly, but adjusted net income and adjusted EBITDA saw significant increases. The company updated its full year 2020 guidance, refining revenue ranges and raising profitability ranges.

Emergent BioSolutions reported a strong Q2 2020, with a significant increase in total revenues, driven by increases in product sales and contract development and manufacturing services. The company also revised upward its full year 2020 guidance.

Emergent BioSolutions reported total revenues of $192.5 million, a slight increase over 2019, driven by increases in CDMO and contracts and grants revenues offsetting a decline in product sales. The company recorded a net loss of $12.5 million, or $0.24 per diluted share, compared to a net loss of $26.0 million in 2019. Adjusted EBITDA was $15.3 million, compared to $8.4 million in 2019.

Emergent BioSolutions reported a strong Q4 2019 with a 33% increase in total revenues, driven by increased sales of ACAM2000 and NARCAN Nasal Spray. Net income significantly improved, and the company reaffirmed its 2020 financial forecast.